LDS/Medical Tests/FBN1 (Fibrillin-1) Genetic Mutation Analysis

FBN1 (Fibrillin-1) Genetic Mutation Analysis

Fibrillin-1is an approximately 350 kDa cysteine rich-glycoprotein mainly composed of tandemly repeating domains of epidermal growth factor (EGF)-like modules and is encoded by the FBN1 gene. Fibrillin-1 is ubiquitously expressed in the connective tissue of the skin, heart, muscle, cornea, tendon, vasculature, lungs, kidney, and bone. The FBN1 gene is approximately 200kb and is made up of a large coding sequence divided into 65 exons located on chromosome 15.

More than 1000 mutations have been identified in the gene for FBN1. Mutations of this gene may prevent the formation of microfibrils, which results in abnormal connective tissues. FBN1 mutations have been identified as the cause of Marfan syndrome, dominant Weill-Marchesani syndrome, geleophysic dysplasia, acromicric dysplasia, stiff skin syndrome, isolated ectopia lentis, kyphoscoliosis, familial arachnodactyly, familial thoracic ascending aortic aneurysms and Marchesani syndrome (MASS). At least 90% of Marfan syndrome cases are associated with mutations in FBN1.

Marfan syndrome is an autosomal dominant disorder of connective tissue, with major features in the musculoskeletal, cardiovascular, and ocular systems and minor features in the lung and skin. Clinical symptoms of Marfan syndrome are aortic root dilation, pulmonary emphysema, atrioventricular valve changes and skeletal muscle myopathy.

  • Aids in the diagnosis of FBN1-associated Marfan syndrome
  • Aids in the diagnosis of autosomal dominant ectopia lentis
  • Aids in the diagnosis of isolated ascending aortic aneurysm and dissection
  • Aids in the diagnosis of isolated skeletal features of Marfan syndrome
  • Aids in the diagnosis of Shprintzen-Goldberg syndrome
  • Aids in the diagnosis of autosomal dominant Weill-Marchesani syndrome

Positive

  • The finding of a pathogenic variants or duplication/deletion in the FBN1 gene is supportive of a diagnosis of Marfan syndrome or other FBN1-related condition

Negative

  • No reportable sequencing variants or deletions/duplications were detected in FBN1 indicates normal phenotype.

Negative for mutation analyzed (No reportable sequencing pathogenic variants or deletions/duplications were detected)

Real time polymerase chain reaction (RT-PCR), Next generation sequencing method, Bidirectional sequencing of the entire FBN1 coding region and intron-exon boundaries, Sanger sequencing.

Whole Blood (Levander top tube). 

Stability

  • Ambient: 72 hours
  • Refrigerated: 1 week
  • Frozen: Unacceptable
Homocysteine, BNP, Troponin I, CRP highs sensitive, Hypertrophic Cardiomyopathy Gene Mutation Panel, NGS.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login